Outset Medical (OM) Scheduled to Post Quarterly Earnings on Wednesday

Outset Medical (NASDAQ:OM) will be issuing its quarterly earnings data after the market closes on Wednesday, August 7th. Analysts expect the company to announce earnings of ($0.43) per share for the quarter. Outset Medical has set its FY 2024 guidance at EPS.Parties that wish to register for the company’s conference call can do so using this link.

Outset Medical (NASDAQ:OM) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.13). Outset Medical had a negative net margin of 134.93% and a negative return on equity of 120.67%. The business had revenue of $28.17 million during the quarter, compared to the consensus estimate of $30.55 million. On average, analysts expect Outset Medical to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Outset Medical Stock Down 4.4 %

Shares of NASDAQ OM opened at $3.51 on Wednesday. Outset Medical has a one year low of $1.92 and a one year high of $20.75. The company has a debt-to-equity ratio of 2.11, a current ratio of 6.42 and a quick ratio of 5.32. The business’s fifty day moving average price is $3.97 and its 200-day moving average price is $3.30. The stock has a market capitalization of $181.54 million, a PE ratio of -1.04 and a beta of 2.00.

Insider Buying and Selling

In other Outset Medical news, CTO Jean-Olivier Racine sold 8,306 shares of the firm’s stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $3.27, for a total value of $27,160.62. Following the sale, the chief technology officer now owns 265,325 shares of the company’s stock, valued at approximately $867,612.75. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, CTO Jean-Olivier Racine sold 8,306 shares of the stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $3.27, for a total transaction of $27,160.62. Following the transaction, the chief technology officer now directly owns 265,325 shares in the company, valued at approximately $867,612.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director D Keith Grossman sold 38,117 shares of the stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $3.78, for a total value of $144,082.26. Following the transaction, the director now owns 47,805 shares in the company, valued at $180,702.90. The disclosure for this sale can be found here. In the last quarter, insiders have sold 60,370 shares of company stock valued at $220,830. Corporate insiders own 3.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on OM. CL King raised Outset Medical from a “neutral” rating to a “buy” rating and set a $6.00 price target on the stock in a research report on Friday, April 5th. BTIG Research began coverage on Outset Medical in a research report on Monday, April 8th. They set a “buy” rating and a $6.00 price target on the stock. Finally, Royal Bank of Canada raised Outset Medical from a “sector perform” rating to an “outperform” rating and upped their price target for the company from $5.00 to $6.00 in a research report on Friday, June 21st. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, Outset Medical presently has a consensus rating of “Moderate Buy” and an average target price of $5.42.

About Outset Medical

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.